Literature DB >> 29629941

B cells in multiple sclerosis.

Mireia Sospedra1.   

Abstract

PURPOSE OF REVIEW: Although it is becoming increasingly clear that B cells play important roles in multiple sclerosis (MS) pathogenesis, it is incompletely understood how they contribute. The purpose of this review is to provide an overview of the current knowledge about B cells in MS taking into account MS heterogeneity. RECENT
FINDINGS: The efficacy of B cell-depleting therapies has provided strong evidence for the involvement of these cells in MS pathogenesis. Although pathogenic antibodies were found in some MS patients, the observation that plasma cells and antibodies remain largely unchanged after B-cell depletion suggests that B cells are involved in MS by other mechanisms than antibody production.
SUMMARY: MS is an autoimmune disease, in which T and B cells play a crucial role. B cells can be involved in MS by different mechanisms such as presentation of antigens to T cells, transport of antigens from tissues to secondary lymphoid organs, secretion of pro-inflammatory or anti-inflammatory cytokines and in a subgroup of patients also production of pathogenic antibodies. As several B-cell/antibody-directed therapies are available, it is important to understand how these different functions of B cells and antibodies vary among patients in order to identify which could benefit best from the different therapies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29629941     DOI: 10.1097/WCO.000000000000563

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  25 in total

1.  Immunosuppression in Multiple Sclerosis and Other Neurologic Disorders.

Authors:  Kaitlyn Koenig Thompson; Stella E Tsirka
Journal:  Handb Exp Pharmacol       Date:  2022

Review 2.  Autophagy modulation in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Donghui Shen; Kang Liu; Hongyan Wang; Haifeng Wang
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

Review 3.  Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy.

Authors:  M J Mansilla; S Presas-Rodríguez; A Teniente-Serra; I González-Larreategui; B Quirant-Sánchez; F Fondelli; N Djedovic; D Iwaszkiewicz-Grześ; K Chwojnicki; Đ Miljković; P Trzonkowski; C Ramo-Tello; E M Martínez-Cáceres
Journal:  Cell Mol Immunol       Date:  2021-05-06       Impact factor: 22.096

4.  A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis.

Authors:  Laura Calvo-Barreiro; Herena Eixarch; Manuel Ponce-Alonso; Mireia Castillo; Rafael Lebrón-Galán; Leyre Mestre; Carmen Guaza; Diego Clemente; Rosa Del Campo; Xavier Montalban; Carmen Espejo
Journal:  Cells       Date:  2020-04-07       Impact factor: 6.600

Review 5.  [Ocrelizumab for treatment of multiple sclerosis].

Authors:  Jonas Graf; Philipp Albrecht; Norbert Goebels; Orhan Aktas; Hans-Peter Hartung
Journal:  Nervenarzt       Date:  2020-06-10       Impact factor: 1.214

Review 6.  Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?

Authors:  Georgios K Vasileiadis; Efthymios Dardiotis; Athanasios Mavropoulos; Zisis Tsouris; Vana Tsimourtou; Dimitrios P Bogdanos; Lazaros I Sakkas; Georgios M Hadjigeorgiou
Journal:  Auto Immun Highlights       Date:  2018-11-10

7.  Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis.

Authors:  Leyre Mestre; Francisco Javier Carrillo-Salinas; Miriam Mecha; Ana Feliú; Carmen Espejo; José Carlos Álvarez-Cermeño; Luisa María Villar; Carmen Guaza
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

8.  CD4+ T Cells in the Blood of MS Patients Respond to Predicted Epitopes From B cell Receptors Found in Spinal Fluid.

Authors:  Rune A Høglund; Robert D Bremel; E Jane Homan; Silje Bøen Torsetnes; Andreas Lossius; Trygve Holmøy
Journal:  Front Immunol       Date:  2020-04-09       Impact factor: 7.561

9.  Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis.

Authors:  Ayano Shima; Tsuyoshi Hamaguchi; Yasutake Tada; Masahito Yamada
Journal:  Intern Med       Date:  2019-08-28       Impact factor: 1.271

Review 10.  Biological characteristics of transcription factor RelB in different immune cell types: implications for the treatment of multiple sclerosis.

Authors:  Meng-Ge Yang; Li Sun; Jinming Han; Chao Zheng; Hudong Liang; Jie Zhu; Tao Jin
Journal:  Mol Brain       Date:  2019-12-27       Impact factor: 4.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.